Form 4: Pluri CFO Liat Zalts Granted 3,660 RSUs

Pluri Inc.'s Chief Financial Officer, Liat Zalts, received a grant of 3,660 restricted stock units under the company's 2019 Equity Compensation Plan.

Summary

• Liat Zalts, Chief Financial Officer of Pluri Inc. (PLUR), reported an acquisition of common stock.
• The transaction occurred on December 4, 2025.
• Zalts acquired 3,660 shares of common stock at a price of $0 per share.
• These shares represent Restricted Stock Units (RSUs) approved by the Board of Directors under the Company's 2019 Equity Compensation Plan.
• The RSUs will vest equally on a monthly basis over three months following the grant date.
• Following this transaction, Liat Zalts beneficially owns 92,767 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive due to executive alignment through equity compensation, which is a standard practice and generally viewed favorably for governance and retention.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief Financial Officer aligns management's interests with those of shareholders.
• The equity compensation is part of an existing, approved plan (2019 Equity Compensation Plan).

Negatives

• No specific negatives are indicated in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The granted Restricted Stock Units (RSUs) will vest equally on a monthly basis over three months following the grant date of December 4, 2025.

Management Comments

• The restricted stock units ('RSUs') were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan.

Industry Context

The grant of Restricted Stock Units (RSUs) to a Chief Financial Officer is a common practice in the biotechnology and pharmaceutical industry, as well as across many public companies, to incentivize and retain key executives by aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• Equity compensation, particularly through Restricted Stock Units (RSUs), is a standard component of executive compensation packages across publicly traded companies, including peers in the biotechnology sector such as Gilead Sciences or Amgen, which frequently utilize similar plans to attract and retain top talent.
• The vesting schedule of three months is relatively short compared to typical multi-year vesting schedules (e.g., 3-4 years) often seen for initial RSU grants, suggesting it might be a performance-based or retention grant rather than a standard new hire grant.

Corporate Governance

Related Party Transactions

• This is an insider transaction involving an executive (Liat Zalts, CFO) and the company (Pluri Inc.), which is a form of related party dealing, specifically equity compensation.

Stakeholder Impact

• Shareholders: Minor potential dilution from the issuance of new shares upon vesting, but generally viewed positively for aligning executive incentives with shareholder interests.
• Employees: May signal stability in executive compensation practices and the company's commitment to retaining key talent.

Next Steps

• Vesting of the 3,660 Restricted Stock Units (RSUs) equally over three months following December 4, 2025.

Key Dates

Keywords

Pluri Inc., PLUR, Liat Zalts, Chief Financial Officer, CFO, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity compensation, stock grant